Tomas Leanderson appointed new President & CEO for Active Biotech

25-Jul-2008

Sven Andréasson has notified the Board of his wish to resign from the position as President & CEO of Active Biotech AB. Sven Andréasson has been the company's CEO since 1999 and under his leadership Active Biotech has been transformed from a combined vaccine and research company into a company focused on development of novel pharmaceuticals for treatment of cancer and autoimmune diseases.

The Board of Active Biotech AB has decided to appoint Tomas Leanderson to become the new President & CEO. Tomas Leanderson has been the CSO for Active Biotech since 1999.

Sven Andréasson will remain as CEO until September 1st 2008.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances